Short-term bone loss in HIV-infected premenopausal women

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 2, 2010, Pages 202-208

  Yin, Michael T ^a   Lu, Dalian ^b   Cremers, Serge ^a   Tien, Phyllis C ^c   Cohen, Mardge H ^d   Shi, Qiuhu ^e   Shane, Elizabeth ^a   Golub, Elizabeth T ^f   Anastos, Kathryn ^g  

^a NewYork Presbyterian Hospital   (United States)

^b Analytic Solutions LLC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Bone density; Bone loss; Bone turnover markers; HIV; Osteoporosis; Premenopausal women

Indexed keywords

OPIATE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; OSTEOLYSIS; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; VITAMIN D DEFICIENCY;

ADULT; BONE DENSITY; FEMALE; FRACTURES, BONE; HIV INFECTIONS; HUMANS; INCIDENCE; PREMENOPAUSE;

EID: 75649084530     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181bf6471     Document Type: Article

References (38)

1. Arnsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2006;42: 1014-1020.
2. Dolan SE, Huang JS, Killilea KM, et al. Reduced bone density in HIV-infected women. AIDS. 2004;18:475-483.
3. Prior J, Burdge D, Maan E, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int. 2007;18:1345-1353.
4. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003;46: 221-227.
5. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int. 2005;16:1345-1352.
6. Arnsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2005;42: 1014-1020.
7. Bolland MJ, Grey AB, Gamble GD, et al. Clinical review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007;92: 4522-4528.
8. Huang JS, Wilkie SJ, Dolan S, et al. Reduced testosterone levels in human immunodeficiency virus-infected women with weight loss and low weight. Clin Infect Dis. 2003;36:499-506.
9. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554-561.
10. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8:164-172. (Pubitemid 47121761)
11. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;27:817-824.
12. Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93: 3499-3504.
13. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006;91:2938-2945.
14. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-490.
15. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999;84:145-150.
16. Aukrust P, Liabakk NB, Muller F, et al. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis. 1994;169:420-424.
17. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature. 1996;384:529-534.
18. Konishi M, Takahashi K, Yoshimoto E, et al. Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS. 2005;19:1240-1241.
19. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
20. Hessol NA, Schneider M, Greenblatt RM, et al. Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol. 2001;154:563-573.
21. Anastos K, Lu D, Shi O, et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther. 2007;12:1049-1058.
22. Yin M, Cremers S, Lu D, et al. Short term bone loss in HIV-infected premenopausal women. Paper presented at: 15th Conference on Retro-viruses and Opportunistic Infections; February 3-6, 2008; Boston, MA.
23. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929-1936.
24. Lewiecki EM, Watts NB, McClung MR, et al. Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab. 2004;89:3651-3655.
25. Sennels HP, Jacobsen S, Jensen T, et al. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. Scand J Clin Lab Invest. 2007;67:821-835.
26. Lensmeyer GL, Wiebe DA, Binkley N, et al. HPLC method for 25-hydroxyvitamin D measurement: comparison with contemporary assays. Clin Chem. 2006;52:1120-1126.
27. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in HIV-infected women. J Clin Endocrinol Metab. 2006;91:2938-2945.
28. Bolland MJ, Grey AB, Horne AM, et al. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clin Endocrinol (Oxf). 2007;67:270-275.
29. Fernandez-Rivera J, Garcia R, Lozano F, et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials. 2003;4: 337-346.
30. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15:1275-1280.
31. Brown T, Ruppe M, Kassner R, et al. Reduced bone mineral density in HIV infected patients and its association with increased central adiposity and post-load hyperglycemia. J Clin Endocrinol Metab. 2004;89: 1200-1206.
32. Bruera D, Luna N, David DO, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003; 17:1917-1923.
33. Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIVon bone in the elderly. Osteoporos Int. 2008;19: 913-918.
34. Aukrust P, Muller F, Lien E, et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis. 1999;179: 74-82.
35. Gibellini D, Borderi M, De Crignis E, et al. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol. 2007;79:1446-1454.
36. Lew E, Gallagher L, Kuehnert M, et al. Intracellular cytokines in the acute response to highly active antiretroviral therapy. AIDS. 2001;15: 1665-1670.
37. Mora S, Zamproni I, Cafarelli L, et al. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS. 2007;21:1129-1135.
38. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005;90: 6323-6331.